Platelet transfusions in haploidentical haematopoietic stem cell allograft candidates: Protecting HLA‐A and HLA‐B antigens through eplet analysis
HLA · 2024
DOI: 10.1111/tan.15438 ↗Kurz gefasst
Fachartikel in der Zeitschrift HLA, 2024. Verfasst von Gatien Durand und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology and Histocompatibility, Amiens University Hospital, Amiens, France. Hauptthemen laut MEDLINE: Platelet Transfusion, Graft Rejection. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
In patients awaiting an allogeneic haematopoietic stem cell transplantation, platelet transfusion is a risk factor for anti‐HLA class I immunization because the resulting donor‐specific antibodies complicate the allograft process. The objective of the present study was to determine the feasibility of a novel eplet‐based strategy for identifying HLA class I mismatches between potential donors and the recipient when pre‐allograft platelet transfusions were required. We included 114 recipient/haploidentical relative pairs. For each pair, we entered HLA‐class I typing data into the HLA Eplet Mismatch calculator, defined the list of mismatched eplets (for the recipient versus donor direction) and thus identified the shared HLAs to be avoided. Using this list of HLAs, we defined the theoretical availability of platelet components (PCs) by calculating the virtual panel‐reactive antibody (vPRA). We also determined the number of PCs actually available in France by querying the regional transfusion centre's database. The mean ± standard deviation number of highly/moderately exposed eplets to be avoided in platelet transfusions was 5.8 ± 3.3, which led to the prohibition of 38.5 ± 2 HLAs‐A and ‐B. Taking into account the mismatched antigens and the eplet load, the mean ± standard deviation theoretical availability of PCs (according to the vPRA) was respectively 34.49% ± 1.95% for HLA‐A and 80% ± 2.3% for HLA‐B. A vPRA value below 94.9% for highly or moderately exposed eplets would predict that 10 PCs were actually available nationally. Although epitope protection of HLA molecules is feasible, it significantly restricts the choice of PCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Haematology and Histocompatibility, Amiens University Hospital, Amiens, France.
- EA HEMATIM 4666, Jules Verne University of Picardie, Amiens, France.
- Department of Blood Transfusions, Amiens University Hospital, Amiens, France.
- Department of Biology, Etablissement Français du Sang (EFS) Hauts de France, Amiens, France.
- Department of Clinical Haematology and Cellular Therapy, Amiens University Hospital, Amiens, France.
ORCID-Profile: Nicolas Guillaume
Zitieren
APA
Durand, G., Desoutter, J., Lorriaux, C., Poumaredes, G., Joris, M., Charbonnier, A., Lebon, D., Paubelle, E., Garcon, L., & Guillaume, N. (2024). Platelet transfusions in haploidentical haematopoietic stem cell allograft candidates: Protecting HLA‐A and HLA‐B antigens through eplet analysis. HLA. https://doi.org/10.1111/tan.15438
Vancouver
Durand G, Desoutter J, Lorriaux C, Poumaredes G, Joris M, Charbonnier A, et al. Platelet transfusions in haploidentical haematopoietic stem cell allograft candidates: Protecting HLA‐A and HLA‐B antigens through eplet analysis. HLA. 2024. doi:10.1111/tan.15438
BibTeX
@article{Durand2024,
author = {Durand, Gatien and Desoutter, Judith and Lorriaux, Corinne and Poumaredes, Géraldine and Joris, Magalie and Charbonnier, Amandine and Lebon, Delphine and Paubelle, Etienne and Garcon, Loïc and Guillaume, Nicolas},
title = {Platelet transfusions in haploidentical haematopoietic stem cell allograft candidates: Protecting HLA‐A and HLA‐B antigens through eplet analysis},
journal = {HLA},
year = {2024},
doi = {10.1111/tan.15438}
}
EUVIMED